Cancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lung cancer.
The vaccine treatment developed by VOLT, a strategic collaboration between Vaccitech Ltd and the Ludwig Institute for Cancer Research, is designed to stimulate the body's immune system to attack cancer cells. It will deliver cancer-associated antigens (MAGE A3 and NY-ESO-1) to antigen presenting cells called dendritic cells, causing the immune system to produce cytotoxic T cells, which target and kill cancerous cells expressing the antigens.
First appointment at lung transplant centre.
Hi All, New here... Restrictive Lung issue?
Came across this online and thought it might be helpful
Hurts breathing in on left side/lung...
